

Title (en)
A METHOD FOR IMPROVEMENT OF TOLERANCE FOR THERAPEUTICALLY EFFECTIVE AGENTS DELIVERED BY INHALATION

Title (de)
VERFAHREN ZUR VERBESSERUNG DER TOLERANZ GEBENÜBER THERAPEUTISCH WIRKSAMEN MITTELN, DIE DURCH INHALATION ABGEGEBEN WERDEN

Title (fr)
PROCEDE PERMETTANT D'AMELIORER LA TOLERANCE A DES AGENTS EFFICACES SUR LE PLAN THERAPEUTIQUE ADMINISTRES PAR INHALATION

Publication
EP 1807123 A4 20100113 (EN)

Application
EP 05790821 A 20050128

Priority

- US 2005003532 W 20050128
- US 61165604 P 20040920
- US 2004036926 W 20041104
- US 63502204 P 20041209

Abstract (en)
[origin: WO2006060027A2] A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.

IPC 8 full level
A61K 9/12 (2006.01); **A61K 9/14** (2006.01); **A61K 31/24** (2006.01); **A61K 31/47** (2006.01)

CPC (source: EP)
A61K 9/0075 (2013.01); **A61K 9/0078** (2013.01)

Citation (search report)

- [XY] US 2003171402 A1 20030911 - GLEICH GERALD J [US], et al
- [XY] WO 9837896 A1 19980903 - MAYO FOUNDATION [US]
- [XY] DECCO M L ET AL: "Nebulized lidocaine in the treatment of severe asthma in children: a pilot study", ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY, ARLINGTON HEIGHTS, IL, US, vol. 82, no. 1, 1 January 1999 (1999-01-01), pages 29 - 32, XP009126326, ISSN: 1081-1206
- [XY] HUNT L W ET AL: "EFFECT OF NEBULIZED LIDOCAINE ON SEVERE GLUCOCORTICOID-DEPENDENT ASTHMA", MAYO CLINIC PROCEEDINGS, MAYO MEDICAL VENTURES, ROCHESTER, MN, vol. 71, no. 4, 1 April 1996 (1996-04-01), pages 361 - 368, XP002069072, ISSN: 0025-6196
- [Y] PARI AEROSOL RESEARCH INSTITUTE: "PARI's eFlow(R), an Electronic Aerosol Device for Medication Delivery, Receives FDA 510(k) Market Clearance", 18 May 2004 (2004-05-18), Monterey, California, USA, pages 1 - 2, XP002558312, Retrieved from the Internet <URL:http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-18-2004/0002176356&EDATE> [retrieved on 20091201]
- [XY] IACONO A T ET AL: "DOSE-RELATED REVERSAL OF ACTUE LUNG REJECTION BY AEROSOLIZED CYCLOSPORINE", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 155, no. 5, 1 May 1997 (1997-05-01), pages 1690 - 1698, XP000939164, ISSN: 1073-449X
- See references of WO 2006060027A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2006060027 A2 20060608; WO 2006060027 A3 20071213; AU 2005310312 A1 20060608; CA 2581053 A1 20060608; EP 1807123 A2 20070718; EP 1807123 A4 20100113

DOCDB simple family (application)
US 2005003532 W 20050128; AU 2005310312 A 20050128; CA 2581053 A 20050128; EP 05790821 A 20050128